Targeting cyclin D1 in non-small cell lung cancer and mesothelioma cells by antisense oligonucleotides

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3683-3690

  Saini, Shamsher S ^a   Klein, Mark A ^a,b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antisense oligonucleotide; Apoptosis; Cyclin D; Cyclin E; Cyclin dependent kinase; Kinases; Non small lung cancer cells; Phosphatases; Pleural mesothelioma cells; Retinoblastoma protein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD1 ANTIGEN; CD3 ANTIGEN; CYCLIN D1; CYCLIN E;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL; CELL LYSATE; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D1; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MESOTHELIOMA; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 83055187106     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bloom J and Cross FR: Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol 8: 149-160, 2007. (Pubitemid 46432532)
2. Bates S, Bonetta L, MacAllan D, Parry D, Holder A, Dickson C and Peters G: CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene 9: 71-79, 1994. (Pubitemid 24020935)
3. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston and DM: Functional interactions of the retinoblastoma protein with mammalian D type cyclins. Cell 73: 487-497, 1993. (Pubitemid 23143348)
4. Hall FL, Williams RT, Wu L, Wu F, Carbonaro-Hall DA, Harper JW and Warburton D: Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein. Oncogene 8: 1377-1384, 1993. (Pubitemid 23129863)
5. Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993. (Pubitemid 23139228)
6. 1 cyclins. Cell 71: 323-334, 1992.
7. Weinberg RA: The retinoblastoma protein and cell cycle control: Cell 81: 323-330, 1995.
8. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D and Peters G: Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90: 43-50, 1995.
9. Schauer IE, Siriwrdana S, Langan TA and Scalfani RA: Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 91: 7827-7831, 1994. (Pubitemid 24238278)
10. Yasui M, Yamamoto H, Ngan CY, Damdinsuren B, Sugita Y, Fukunaga H, Gu J, Maeda M, Takemasa I, Ikeda M, Fujio Y, Sekimoto M, Matsuura N, Weinstein IB and Monden M: Antisense to cyclin D1 inhibits vascular endothelial growth factor-stimulated growth of vascular endothelial cells: implication of tumor vascularization. Clin Cancer Res 12(15): 4720-4729, 2006. (Pubitemid 44297826)
11. Arber N, Doki Y Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR and Weinstein IB: Antisense to cyclin D1 inhibits the growth and tumorigenicity of colon cancer cells. Cancer Res 57: 1569-1574, 1997. (Pubitemid 27175576)
12. Hung WC, Huang JS and Chuang LY: Antisense oligodeoxy-nucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression. Biochem Biophys Res Commun 220: 719-723, 1996.
13. Kornmann M, Arber N and Kore M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998. (Pubitemid 28067331)
14. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJP, Cheffetz S and Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinoma. Cancer Res 59: 4876-4881, 1999. (Pubitemid 29472891)
15. Wang MB, Billings KR, Venkatesan N, Hall FL and Srivatsan ES: Inhibition of cell proliferation in head and neck squamous cell carcinoma cell lines with antisense cyclin D1. Otolaryngol Head Neck Surg 119: 593-599, 1998. (Pubitemid 29005479)
16. Simile MM, De Miglio MR, Muroni MR, Frau M, Asara G, Serra S, Muntoni MD, Seddaiu MA, Daino L, Feo F and Pascale RM: Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis 25: 333-341, 2004. (Pubitemid 38344399)
17. Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, Brooks HB, Campbell RM, Considine E, Dempsey JA, Faul MM, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B and Watkins SA: Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 46: 2027-2030, 2003. (Pubitemid 36583483)
18. Zhu G, Conner S, Zhou X, Shih C, Brooks HB, Considine E, Dempsey JA, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B and Watkins SA: Synthesis of quinolinyl/isoquinolinyl [a]pyrrolo [3,4-c] carbazoles as cyclin D1/CDK4 inhibitors. Bioorg Med Chem Lett 13: 1231-1235, 2003. (Pubitemid 36351323)
19. Jeong HW, Kim MR, Son KH, Han MY, Ha JH, Garnier M, Meijer L and Kwon BM: Cinnamaldehydes inhibit cyclin dependent kinase 4/cyclin D1. Bioorg Med Chem Lett 10: 1819-1822, 2000. (Pubitemid 30657614)
20. Markwalder JA, Arnone MR, Benfield PA, Boisclair M, Burton CR, Chang CH, Cox SS, Czerniak PM, Dean CL, Doleniak D, Grafstrom R, Harrison, BA, Kaltenbach RF 3rd, Nugiel DA, Rossi KA, Sherk SR, Sisk LM, Stouten P, Trainor GL, Worland P and Seitz SP: Synthesis and biological evaluation of 1-aryl-4,5-dihydro-1H- pyrazolo[3,4-d]pyrimidin-4-one inhibitors of cyclin-dependent kinases. J Med Chem 47: 5894-5911, 2004. (Pubitemid 39517014)
21. Kubo A and Kaye FJ: Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway. J Natl Cancer Inst 93: bb415-417, 2001.
22. Sanchez-Martinez C, Shih C, Faul MM, Zhu G, Paal M, Somoza C, Li T, Kumrich CA, Winneroski LL, Xun Z, Brooks HB, Patel BK, Schultz RM, DeHahn TB, Spencer CD, Watkins SA, Considine E, Dempsey JA, Ogg CA, Campbell RM, Anderson BA and Wagner J: Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors. Bioorg Med Chem Lett 13: 3835-3839, 2003 (Pubitemid 37206519)
23. Senderowicz AM: Small-molecule cyclin-dependent kinase modulators. Oncogene 22: 6609-6620, 2003.
24. Senderowicz AM: Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 52(Suppl 1): S61-S73, 2003.
25. Faul MM, Engler TA, Sullivan KA, Grutsch JL, Clayton MT, Martinelli MJ, Pawlak JM, LeTourneau M, Coffey DS, Pedersen SW, Kolis SP, Furness K, Malhotra S, Al-awar RS and Ray JE: Synthetic approaches to indolo[6,7-a]pyrrolo[3,4-c] carbazoles: potent cyclin D1/CDK4 inhibitors. J Org Chem 69: 2967-2975, 2004. (Pubitemid 38542548)
26. Engler TA, Furness K, Malhotra S, Sanchez-Martinez C, Shih C, Xie W, Zhu G, Zhou X, Conner S, Faul MM, Sullivan KA, Kolis SP, Brooks HB, Patel B, Schultz RM, DeHahn TB, Kirmani K, Spencer CD, Watkins SA, Considine EL, Dempsey JA, Ogg CA, Stamm NM, Anderson BD, Campbell RM, Vasudevan V and Lytle ML: Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg Med Chem Lett 13: 2261-2267, 2003. (Pubitemid 36724962)
27. Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, Brodfuehrer J, Choi C, Barvian MR and Fry DW: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48: 2388-2406, 2005. (Pubitemid 40516432)
28. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J 3rd, Booth RJ, Elliott WL, Dobrusin EM, Fry DW and Toogood PL: Pyrido[2,3-d] pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem 48: 2371-2387, 2005. (Pubitemid 40516431)
29. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK and Toogood PL: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3: 1427-1438, 2004.
30. Sun Y, Li YX, Wu HJ, Wu SH, Wang YA, Luo DZ and Liao DJ: Effects of an Indolocarbazole Derived CDK4 Inhibitor on Breast Cancer Cells. J Cancer 2: 36-51, 2011.
31. Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V and Dmitrovsky E: Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 13: 1983-1990, 1996. (Pubitemid 26397458)
32. Langenfeld J, Kiyokawa H, Sekula D, Boyle J and Dmitrovsky E: Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94: 12070-12074, 1997. (Pubitemid 27467844)
33. Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, Dawson MI and Dmitrovsky E: Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst (Bethesda) 91: 373-379, 1999. (Pubitemid 29102338)
34. Dragnev KH, Pitha-Rowe I, Ma Y, Petty WJ, Sekula D, Murphy B, Rendi M, Suh N, Desai NB, Sporn MB, Freemantle SJ and Dmitrovsky E: Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clin Cancer Res 10: 2570-2577, 2004. (Pubitemid 38445720)
35. Frizelle, SP, Kratzke MG, Carreon RR, Engel SC, Youngquist L, Klein MA, Fourre L, Shekels LL and Kratzke RA: Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer Res 28: 1-7, 2008.
36. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
37. Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ and Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278: 30339-30347, 2003. (Pubitemid 36962428)
38. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M and Stacey DW: Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 24: 2599-261, 2005.
39. 3 independent of Thr-283 phosphorylation. Oncogene 25: 2468-2476, 2006.
40. Blom N, Gammeltoft S and Brunak S: Sequence- and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 294: 1351-1362, 1999. (Pubitemid 30008805)